SBIR/STTR Research Award

A BIOMATERIAL FOR ESOPHAGEAL REPAIR

Award identifier f52130c05b04a05985c1990d3928cf05201212d630cceec113d7f6ace0a28cd5Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
ACELL, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Unedited Applicant's Abstract):When people with diabetes reach end-stage renal disease they must undergo either dialysis or transplantation. About 200,000 Americans need artificial kidney machines to stay alive. These machines rely on sterile dialysis membranes to remove toxic materials from the bloodstream. More than 30 different polymers or polymer blends are used in dialysis membranes, and most of these degrade under conditions of steam or gamma radiation sterilization. Ethylene oxide (EO) remains the sterilant of choice for these membranes. However, the traditional blend used 88 percent CFC-12 as a fire suppressant and propellant, and CFCs have been phased out of production because of their high ozone-depletion potentials (ODPs). Alternatives include explosive 100 percent EO and blends of EO with high global warming potential (GWP) hydrofluorocarbons (HFCs), less effective carbon dioxide, or hydro chlorofluorocarbon (HCFC) compounds facing future phase out. This proposed Phase I effort wilt determine the feasibility of using blends containing EO, trifluoromethyl iodide (CF3I), and HFCs for sterilizing dialysis membranes. Trifluoromethyl iodide is an excellent combustion suppressant and has physical properties similar to CFC-12 with zero ODP and extremely low GWP. Flammability and fractionation tests will be conducted to determine optimal blend compositions. Compatibility and residual CF3I measurements with common membrane materials will be conducted. PROPOSED COMMERCIAL APPLICATION: The research, if successful, will develop a new nonflammable sterilant gas for dialysis membranes that does not contain ozone-depleting substances, is more effective that current alternatives, and has reduced GWP. The new sterilant gas should also be useful for sterilizing many other types of medical equipment. The new sterilant gas should be marketable worldwide and should allow use of existing EO sterilizing equipment, thus reducing costs of medical care.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.